Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) had its price objective hoisted by stock analysts at Piper Sandler from $13.00 to $15.00 in a report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s target price indicates a potential upside of 39.15% from the stock’s previous close. […]